



ISLHD CARDIOVASCULAR CLINICAL TRIALS

Illawarra Heart Health Centre
April 2024

ISLHD CARDIOVASCULAR CLINICAL TRIALS UNIT

Illawarra Heart
Health Centre

Wollongong Hospital
Loftus Street
Wollongong NSW 2500

Ph 02 4253 4908

Fax 02 4253 4950

Email
ISLHD-
cardiacresearch@health.nsw.
gov.au

The Illawarra Shoalhaven Local Health District (ISLHD) Cardiovascular Clinical Trials Unit is situated at the Illawarra Heart Health Centre in Wollongong Hospital. It boasts a specialised team comprising doctors, nurses, and allied health professionals.

This unit actively supports a range of clinical trials, contributing to evidence-based practices, fostering knowledge development and enhancing patient care within the local community.

Do you have cardiovascular disease and elevated cholesterol levels?

Ask to see if you qualify to participate in the PREVAIL study.

PREVAIL is a clinical research study evaluating the safety and effectiveness of an investigational drug in people who have cardiovascular disease. The study drug is designed to lower cholesterol, specifically low-density lipoprotein cholesterol (LDL-C), known as the harmful or "bad" form of cholesterol.

Study overview:

- Have study clinic and telephone visits for about 3 to 4 years.
- Take 1 tablet of either the study drug or a placebo (no active ingredients) by mouth once daily.
- Continue taking your medication to lower cholesterol during the study that has been prescribed by your general practitioner (if applicable).
- Have 1 follow-up visit after your last dose of the assigned study drug or placebo (via telephone).

REFERRAL OR CONSULTATION




To discuss your patient with an ISLHD Trials Clinician
please phone the Illawarra Heart Health Centre on 02 4253 4908

ISLHD Cardiovascular Clinical Trials





CURRENTLY OPEN FOR RECRUITMENT

Scan the QR Code for more information including eligibility criteria

Medication trials

Hyperlipidaemia	PREVAIL: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants with Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies	A/Prof Lee	
CVD, CKD & inflammation	ZEUS: Ziltivekimab (anti-inflammatory monoclonal antibody) versus placebo in patients with cardiovascular disease, renal impairment and raised hs-CRP. CV outcome study. Monthly injection.	A/Prof Lee	
STEMI	RESTORE MI: Restoring Microcirculatory Perfusion in ST-Elevation Myocardial Infarction A randomised trial to evaluate the efficacy of low-dose intracoronary tenecteplase in STEMI patients with high microvascular resistance post[1]PCI A multicentre double-blind placebo-controlled study in Australia and overseas	Dr Shetty	

Intervention trials

Aortic stenosis	EASY-AS: A trial of early valve replacement in severe asymptomatic aortic stenosis	Dr Danson	
Hyperlipidaemia	GOAL ASIA: Guideline Oriented Approach to Lipid Lowering In Asia-Pacific	A/Prof Lee	
LV thrombus	RELEVANT: Resolution of left ventricular thrombus with different anti coagulation strategies	Dr Moragues	
Implant device	PROTECT ICD: Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction	A/Prof Lee	

For further information regarding these trials at the Illawarra Heart Health Centre you may also contact the trial coordinators as listed or email

ISLHD-cardiacresearch@health.nsw.gov.au

Stephen Mackay — Trial Coordinator
Martin Walker — Research Nurse
Dr Astin Lee — Director of Cardiology

02 4253 4624
02 4253 4650
Astin.LEE@health.nsw.gov.au